MDTBy Calypso Research8 min read

Medtronic plc (MDT) Q4 2025 Earnings Analysis

Heartbeat or Heartbreak with $9B Revenue Drop

Key Takeaways

Medtronic plc (MDT) reported Q4 2025 earnings with revenue of $9.0B, representing a +8.8% year-over-year change. The stock moved -3.1% on earnings day.

The bull case: A diversified set of high-visibility growth drivers in CAS/PFA, renal denervation, Diabetes, Pelvic Health, and Hugo, combined with Elliott-driven portfolio and capital allocation discipline, drives Medtronic’s organic growth above 5% with accelerating EPS and margin expansion through FY27.

The bear case: Execution risks in scaling new platforms (PFA, Ardian, Hugo, new CGMs), lingering slower-growth franchises, and the complexity of the Diabetes spin-off could prevent the anticipated growth inflection and leave Medtronic delivering only modestly better than current mid-single-digit growth with constrained operating leverage.

Financial Highlights

  • Revenue: $9.0B (+8.8% YoY)
  • Gross Profit: $5.9B (64.9% margin, -1.6% YoY)
  • Operating Income: $1.8B (19.7% margin, -0.2% YoY)
  • Net Income: $1.1B
  • TTM Revenue: $35.5B

Stock Performance

  • Earnings Day Move: -3.1%
  • Year-to-Date: +2.7%
  • 1-Year Return: +9.4%
  • vs. S&P 500 (since earnings): -7.0%
  • vs. Nasdaq (since earnings): -4.2%

View live MDT data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Medtronic plc's Q4 2025 earnings call:

Magnitude and Timing of Growth Inflection from CAS/PFA and Overall U.S. Growth

Sentiment: Positive

"our CAS business from technology to commercial execution, geographic expansion, safety profile data, physician experience, et cetera, is doing really well,' and 'we're going to have both higher growth rate in Q2 than we did in Q1 in CAS. And we're also going to have an absolute value, significant sequential growth between the first quarter and the second quarter." — Geoffrey Martha
"we're talking $1 billion of incremental revenue over the '25 run rate within a relatively short time frame, right?... these 2 things alone are going to have a pretty significant impact on our growth rates,' and 'you should see these large opportunities as being incremental, and that's what we're targeting." — Thierry Pieton

Elliott Partnership, New Board Committees, and Portfolio / Capital Allocation Strategy

Sentiment: Positive

"we're entering, like I said in the call, a new chapter here for the company... we can turn the page to a new chapter and be more aggressive on some of these other drivers,' and 'these committees are going to help with that... it's all about value creation, and we're going to do what it takes to get there." — Geoffrey Martha
"one is more M&A, okay?... A reinvigorated laser focus on the portfolio to reorient the whole portfolio between M&A and any kind of portfolio moves towards higher growth,' and 'the second is investing more in the company... We think no, we'd want to invest more... because they're secular growth drivers... transformational growth drivers that we haven't seen in decades." — Geoffrey Martha

Scale and Strategic Importance of Renal Denervation (Ardian/Symplicity)

Sentiment: Positive

"all the dominoes are falling. The puzzle pieces snapping into place that this is going to be a massive market... I still think Ardian has a chance to even be bigger. The patient population is massive,' and 'we think this is going to be a -- could be the biggest thing that we ever do." — Geoffrey Martha
"this is one of those areas that we talked about is investing behind this to really make this market develop and grow and be a driver for us and create a moat around our franchise,' and 'we've got already our next generation of catheters ready to go... we think in the early work meaningfully helps the blood pressure reduction." — Geoffrey Martha

Diabetes (MiniMed) Performance, Sensor Rollout, and Spin-Off Execution

Sentiment: Positive

"we have this dynamic where patients are waiting for the new CGMs... we're going to be producing double what we made in Q1 and in the second half double what we're making in the first half. So production is ramping up really nicely,' and 'it's actually a very big moment for us because we're now going to have 2 competitive sensors on the market, giving patients choice, significant improvements in form factor and days of wear." — Que Dallara
"the process is perfectly on track... The first investor engagements have been very, very encouraging,' and 'we said 3 months ago, we thought we'd complete the separation within 18 months. It's 3 months later, now it feels like 15 months. So everything on track." — Thierry Pieton

Sustainability of Growth Across Slower Businesses and Need for Additional M&A

Sentiment: Positive

"some of the businesses that came in below trend or lower growth in the portfolio, they have very specific growth accelerators already organic... you're going to see a meaningful acceleration,' and 'you look around the portfolio, you see major growth drivers and you see some, I'll call them, singles or doubles... that are going to get the rest of the company up and really support this back half ramp and keep it durable." — Geoffrey Martha
"Spine had a mid-single-digit revenue overall... we had over 8% in capital worldwide... we've got a moat around that Spine business that's going to be durable,' and 'Cardiac Rhythm... there's a lot of innovation there... Leadless is still growing over 14%... EV-ICD growing over 80%... I think that business is in a great shape." — Geoffrey Martha

Bull Case

A diversified set of high-visibility growth drivers in CAS/PFA, renal denervation, Diabetes, Pelvic Health, and Hugo, combined with Elliott-driven portfolio and capital allocation discipline, drives Medtronic’s organic growth above 5% with accelerating EPS and margin expansion through FY27.

Bear Case

Execution risks in scaling new platforms (PFA, Ardian, Hugo, new CGMs), lingering slower-growth franchises, and the complexity of the Diabetes spin-off could prevent the anticipated growth inflection and leave Medtronic delivering only modestly better than current mid-single-digit growth with constrained operating leverage.

Looking Ahead

Investors will be closely watching Medtronic plc's next quarterly report for continued execution, particularly around magnitude and Timing of Growth Inflection from CAS/PFA and Overall U.S. Growth. With operating margins at 19.7%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Medtronic plc's revenue in Q4 2025?

Medtronic plc reported Q4 2025 revenue of $9.0B, representing a +8.8% year-over-year change.

Did Medtronic plc beat earnings expectations in Q4 2025?

The stock declined -3.1% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: A diversified set of high-visibility growth drivers in CAS/PFA, renal denervation, Diabetes, Pelvic Health, and Hugo, combined with Elliott-driven portfolio and capital allocation discipline, drives Medtronic’s organic growth above 5% with accelerating EPS and margin expansion through FY27.

What is the bull case for MDT stock?

The bull case for MDT centers on: A diversified set of high-visibility growth drivers in CAS/PFA, renal denervation, Diabetes, Pelvic Health, and Hugo, combined with Elliott-driven portfolio and capital allocation discipline, drives Medtronic’s organic growth above 5% with accelerating EPS and margin expansion through FY27.

What is the bear case for MDT stock?

The bear case for MDT centers on: Execution risks in scaling new platforms (PFA, Ardian, Hugo, new CGMs), lingering slower-growth franchises, and the complexity of the Diabetes spin-off could prevent the anticipated growth inflection and leave Medtronic delivering only modestly better than current mid-single-digit growth with constrained operating leverage.

How has MDT stock performed since its Q4 2025 earnings?

MDT moved -3.1% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +7.0% since earnings. Year-to-date, the stock has returned +2.7%.

Browse all 400+ earnings reports →

Learn More

Analyze MDT in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Medtronic plc and 400+ other stocks, explore the full platform.

Open MDT on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.